EXERGEN EXPANDS MEDICAL THERMOMETRY DISTRIBUTION INTO BRAZIL WITH CNPH

This Partnership and ANVISA Approval Positions Exergen for Strong International
Growth

Watertown, Mass, March 27, 2024 – Exergen Corporation, the leader in infrared temperature
measurement technology for medical applications, has embarked on a significant partnership
with CNPH (Comercial Nacional de Produtos Hospitalares), a prominent distributor based in
São Paulo, Brazil with 10 regional locations. This collaboration marks a pivotal step in Exergen’s
global expansion strategy, aiming to introduce its advanced Temporal Artery Thermometer
models to the Brazilian healthcare and mining sectors.

Focused on innovation and service

Established in 1994, CNPH specializes in importing and distributing a wide range of medical
products. Under the leadership of CEO Carlos Eduardo Santos, the company is known for its
commitment to high-performance products, innovation, and exceptional service, adhering to
both national and international standards. CNPH’s expertise in the medical hospital area,
combined with its robust technical-commercial team located in 10 offices throughout the
country, positions it uniquely to facilitate Exergen’s entry into Brazil’s healthcare market.

ANVISA Approval

The TAT-5000S Temporal Artery Thermometer from Exergen Corporation has been approved
(ANVISA) for use in Brazil. The approval marks a pivotal step in ensuring that healthcare
providers have access to state-of-the-art, reliable, and precise temperature monitoring tools,
essential for patient care in hospitals, healthcare facilities, and elderly homes.

Exergen’s Advanced Temporal Artery Thermometers

“Exergen is dedicated to giving healthcare professionals around the world the medical
thermometry they need to deliver the best patient outcomes possible. We understand Brazil’s
medical professionals need to deliver services to a population of 214 million. Exergen is excited
to partner with CNPH to elevate the standard of patient care and ensure better health outcomes
countrywide,” Dr. Frank Pompei, founder and CEO of Exergen Corporation. “This collaboration
is a testament to the power of innovative technology in transforming healthcare practices,
making advanced medical tools more accessible to health practitioners and patients alike.

ANVISA approval by Brazilian health authorities underscores the country’s commitment to
integrating innovative medical technologies to enhance patient care and safety.”
Exergen’s Temporal Artery Thermometers are known for their accuracy and non-invasive
nature, includes:

  • TAT-5000S: A powerful Temporal Artery Thermometer for use in large hospitals, it also
    integrates seamlessly with major spot monitors, supporting high patient volumes. The TAT5000 comes with a Lifetime Warranty.
  • TAT-2000: A professional lite thermometer designed for use in small clinics and schools,
    offering rapid temperature measurements and a 7-year warranty.
  • TAT-2000C: A consumer-friendly model that provides advanced technology at an accessible
    price, suitable for Brazil home use.

These thermometers offer many advantages, such as exceptional accuracy, patient safety,
rapid measurements (within 2-3 seconds), price efficiency, durability, easy maintenance, and
extensive clinical validation. In addition, there is no need for caps eliminating the need for high
recurring costs and select models come with a lifetime warranty. They represent a leap forward
in non-invasive temperature measurement, crucial in medical settings.

About Exergen
Exergen Corporation, the leader in non-invasive temperature measurement technologies for
industrial and medical applications, delivers non-invasive temperature meters at lower costs,
with higher accuracy, less process control and higher reliability than previously possible. With its
award-winning arterial thermometer, Exergen is known in both the healthcare and consumer
markets. The company was founded by MIT educated and Harvard researcher Dr. Francesco
Pompei, who owns more than 70 patents. Exergen Corporation is headquartered in Watertown,
Massachusetts, United States.

Media Contact:

Christina Guilbert

cguilbert@exergen.com

www.exergen.com

Exergen P/N: 850130, Rev 1